Navigation Links
OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on Investor Relations page of the OncoGenex website at A replay of the webcast will also be available on the Company's website for a period of 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities and the timing of these activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
(Date:10/13/2015)... 2015  Graduate students across the country, with ... will soon have the opportunity to learn about ... drug discovery and development process. Eli Lilly and ... 10 leaders from academic institutions to create an ... of Drug Development."  Lilly will formally unveil the ...
(Date:10/13/2015)... 13, 2015 anesthesia and respiratory ... billion by 2022, according to a new report by ... to their capability to resolve various environmental and lifestyle ... growth. --> anesthesia and respiratory devices market ... 2022, according to a new report by Grand View ...
(Date:10/13/2015)... 2015   Micell Technologies , Inc. today announced ... trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary ... presented at the 27th Annual Transcatheter Cardiovascular Therapeutics ( ... , October 11-15. TCT is the world,s largest ... was designed to optimize vessel healing in patients with ...
Breaking Medicine Technology:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 ... ... growing natural beverage companies in the United States, today announced the release of ... Brew Coffee, and new Cranberry Cocktail Agua Fresca. All feature the unique flavor ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ProText ... Pro X . With ProText Kinetic Panel, users can create energetic text animations in ... a preset into the Final Cut Pro X timeline and stylize the text. With ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Symposium Chairman, ... the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. ... immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key ...
(Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... In ... 2015 utility costs were 36 percent lower per square foot than in 2009. The ... actual cost of heating and cooling has decreased by eight percent. , According ...
Breaking Medicine News(10 mins):